The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1a in combination with GM-CSF in the treatment of COLORECTAL CARCINOMA (CRC)

[1]  P. Biberfeld,et al.  Blood and lymph node T-lymphocyte subsets in non-Hodgkin lymphomas. , 2009, Scandinavian journal of haematology.

[2]  J. Fagerberg,et al.  The therapeutic use of monoclonal antibodies in colorectal carcinoma. , 1991, Seminars in oncology.

[3]  Bruckner Hw,et al.  Chemotherapy of advanced cancer of the colon and rectum. , 1991 .

[4]  M. Tempero,et al.  Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Cordon-Cardo,et al.  Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. , 1990, Cancer research.

[6]  H. Ueo,et al.  Preoperative cell‐mediated immune function and the prognosis of patients with gastric carcinoma , 1990, Journal of surgical oncology.

[7]  A. Hekman,et al.  Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. , 1990, Cancer research.

[8]  R. Connor,et al.  Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. , 1990, Journal of immunology.

[9]  J. Gamble,et al.  IL-3 and granulocyte-macrophage colony-stimulating factor stimulate two distinct phases of adhesion in human monocytes. , 1990, Journal of immunology.

[10]  D. C. Linch,et al.  Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF , 1990, The Lancet.

[11]  S. Wadler,et al.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Hannigan,et al.  Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Thompson,et al.  Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Levin,et al.  Treatment of advanced colorectal cancer. , 1989, Hematology/oncology clinics of North America.

[15]  R. Graziano,et al.  Cytotoxicity mediated by human Fc receptors for IgG. , 1989, Immunology today.

[16]  A. Reske-Kunz,et al.  Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. , 1988, Journal of immunology.

[17]  C. Lindemalm,et al.  Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). , 1988, Hybridoma.

[18]  H. Bruckner,et al.  Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. , 1988, Cancer research.

[19]  A. Burgess,et al.  Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. , 1988, Blood.

[20]  J. Shetye,et al.  Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. , 1988, Hybridoma.

[21]  D. Santoli,et al.  Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. , 1988, Journal of immunology.

[22]  R. Gatenby,et al.  Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. , 1988, Cancer research.

[23]  S. Clarkson,et al.  CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes , 1988, The Journal of experimental medicine.

[24]  G. Martinelli,et al.  The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. , 1987, Archives of surgery.

[25]  D. Golde,et al.  Biosynthetic granulocyte-macrophage colony-stimulating factor enhances neutrophil cytotoxicity toward human leukemia cells. , 1987, Leukemia.

[26]  D. Golde,et al.  Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. , 1986, Blood.

[27]  D. Metcalf.  The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. , 1986, Blood.

[28]  C. Anderson,et al.  Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. , 1985, Journal of immunology.

[29]  R. Williamson,et al.  Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in normal and neoplastic colorectal tissues of humans. , 1985, Journal of the National Cancer Institute.

[30]  D. Golde,et al.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. , 1984, Science.

[31]  M. Herlyn,et al.  Efficient selection of human tumor growth-inhibiting monoclonal antibodies. , 1984, Journal of immunological methods.

[32]  M. Herlyn,et al.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. , 1980, Cancer research.

[33]  R. Pazdur,et al.  5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomas. , 1991, Oncology nursing forum.

[34]  J. Douillard,et al.  Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. , 1991, Human antibodies and hybridomas.

[35]  A. M. Zimmer,et al.  Human IgE, IgG and IgA antibody responses to T101, a murine monoclonal antibody against human lymphocytes: implications for pathogenesis, risk and avoidance of adverse immunologic reactions. , 1990, International archives of allergy and applied immunology.

[36]  V. Price,et al.  Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. , 1986, Science.

[37]  R. Kurlander,et al.  The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes. , 1982, The Journal of clinical investigation.